Celldex Therapeutics CLDX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $35.73M+109% | $28.87M+1.8% | $36.04M-1.0% | $23.04M-46.1% | $17.14M-85.1% | ||
| $415.73M-36.6% | $489.7M-29.7% | $547.19M-24.0% | $607.29M-20.0% | $656.16M-7.4% | ||
| $230K-78.4% | $2.02M+188% | $90K-89.4% | $90K-94.1% | $1.06M-60.2% | ||
| $7.53M-61.2% | $14.08M-33.5% | $21.03M-4.4% | $17.98M+121% | $19.4M+120% | ||
| $459.22M-33.8% | $534.66M-28.4% | $604.34M-22.4% | $648.4M-20.1% | $693.76M-16.9% | ||
| $7.4M+60.7% | $5.33M+22.7% | $4.83M+14.2% | $4.39M+13.7% | $4.6M+13.3% | ||
| $2.01M-42.7% | $2.44M-37.5% | $2.72M-14.3% | $3.12M+27.4% | $3.51M+62.3% | ||
| $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | ||
| $15.43M+48.3% | $13.36M+37.0% | $9.36M-3.9% | $9.3M+8,592% | $10.41M+9,628% | ||
| $511.25M-30.9% | $582.98M-26.4% | $648.44M-21.2% | $692.41M-18.1% | $739.47M-14.9% | ||
| $10.36M+204% | $1.18M-63.9% | $4.27M+283% | $2.07M-45.5% | $3.41M+5.4% | ||
| $1.23M-25.6% | $1.23M+30.6% | $930K-33.4% | $930K-74.7% | $1.65M-57.4% | ||
| $1.47M-2.3% | $1.55M+6.9% | $1.55M+12.6% | $1.54M-3.3% | $1.5M-8.8% | ||
| $51.47M+60.8% | $50.99M+29.1% | $46.47M+44.8% | $32.96M+19.2% | $32.02M+21.8% | ||
| $443K-77.0% | $784K-66.8% | $1.07M-37.5% | $1.5M+87.8% | $1.93M+310% | ||
| $3.11M+22.4% | $4.04M+16.4% | $2.54M-26.8% | $2.54M-26.8% | $2.54M-26.8% | ||
| $55.03M+50.8% | $55.82M+23.1% | $50.08M+34.3% | $37M+15.9% | $36.49M+20.7% | ||
| —— | —— | —— | —— | —— | ||
| $67K+1.5% | $67K+1.5% | $66K0.0% | $66K0.0% | $66K0.0% | ||
| $2.35B+1.6% | $2.34B+1.7% | $2.33B+1.7% | $2.32B+1.7% | $2.31B+1.8% | ||
| -$1.89B-17.6% | -$1.81B-16.6% | -$1.73B-14.9% | -$1.67B-13.6% | -$1.61B-12.5% | ||
| $2.52M-29.3% | $3.63M+9.4% | $3.77M-28.8% | $3.34M+87.6% | $3.57M+59.0% | ||
| $456.23M-35.1% | $527.17M-29.4% | $598.36M-23.9% | $655.41M-19.4% | $702.98M-16.2% | ||
| $511.25M-30.9% | $582.98M-26.4% | $648.44M-21.2% | $692.41M-18.1% | $739.47M-14.9% | ||
| $415.73M-36.6% | $489.7M-29.7% | $547.19M-24.0% | $607.29M-20.0% | $656.16M-7.4% | ||
| $15.43M+48.3% | $13.36M+37.0% | $9.36M-3.9% | $9.3M+8,592% | $10.41M+9,628% | ||
| $2.01M-42.7% | $2.44M-37.5% | $2.72M-14.3% | $3.12M+27.4% | $3.51M+62.3% | ||
| $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | $27.19M0.0% | ||
| $2.01M-42.7% | $2.44M-37.5% | $2.72M-14.3% | $3.12M+27.4% | $3.51M+62.3% | ||
| $15.43M+48.3% | $13.36M+37.0% | $9.36M-3.9% | $9.3M+8,592% | $10.41M+9,628% | ||
| $2.01M-42.7% | $2.44M-37.5% | $2.72M-14.3% | $3.12M+27.4% | $3.51M+62.3% | ||
| $15.43M+48.3% | $13.36M+37.0% | $9.36M-3.9% | $9.3M+8,592% | $10.41M+9,628% | ||
| $38.42M+50.9% | $47.03M+39.0% | $39.72M+40.8% | $28.42M+52.9% | $25.46M+45.2% | ||
| $38.42M+50.9% | $47.03M+39.0% | $39.72M+40.8% | $28.42M+52.9% | $25.46M+45.2% | ||
| $1.23M-25.6% | $1.23M+30.6% | $930K-33.4% | $930K-74.7% | $1.65M-57.4% | ||
| $1.91M-44.3% | $2.34M-38.7% | $2.62M-15.1% | $3.03M+27.1% | $3.43M+62.2% | ||
| $2.35B+1.6% | $2.34B+1.7% | $2.33B+1.7% | $2.32B+1.7% | $2.31B+1.8% | ||
| $67K+1.5% | $67K+1.5% | $66K0.0% | $66K0.0% | $66K0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Celldex Therapeutics cover its short-term obligations?
- Its current ratio is 8.92 — current assets exceed current liabilities.
- Where does Celldex Therapeutics's balance sheet data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.